Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ParaCel
- Development stage
- Unknown
- Lead developer
- Glaukos
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
ParaCel is a proprietary riboflavin formulation developed by Dr. Roberto Pinelli for epithelium-on (epi-on) corneal collagen cross-linking. It is used to treat keratoconus, a condition characterized by progressive thinning and weakening of the cornea. Avedro acquired the intellectual property rights to ParaCel from the Switzerland Eye Research Institute in 2011, aiming to provide a safer, faster, and less invasive treatment option for keratoconus by avoiding the pain and risks associated with epithelium removal.
- Brand names
- ParaCel
02
Targets
COL1A2 (Type I collagen alpha-2 chain)
Beyond the preview
Go deeper on ParaCel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ParaCel.